Horizon Discovery Ltd

Type: Company
Name: Horizon Discovery Ltd
First reported 13 hours ago - Updated 13 hours ago - 1 reports

Getech to brief investors at first ever Stock

Market ShowSource: SMWGetech (GTC)(GTC.L)[LON.GTC] will be briefing investors at the first ever Stock Market Show taking place next month.For over 25 years it has been using its data and geoscience expertise to help the oil and mining industries locate ... [Published Telegraph - 13 hours ago]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Life science investor interest highest for 10 year...

Investor interest in the Cambridge UK life science cluster is running at its highest level for more than a decade, according to serial biotechnology entrepreneur Andy Richards.But increased international funding is needed to produce more winners for patients ... [Published Business Weekly UK - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

GEN Touch: A New App For Our Readers

GEN videos are informative, entertaining, and encompass all aspects of biotechnology.The new GEN Touch app lets you keep up with the latest biotech news and insights on your smart phone or tablet. We've designed versions for quick and easy reading on ... [Published Genetic Engineering News - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Growth on the agenda

Our big September forum will look at how small caps can make it bigInvestors are always on the lookout for the next big equity growth story and at the The Stock Market Show , a major event hosted by Shares and the London Stock Exchange ( LSE ) on Saturday ... [Published Shares Magazine - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Article: What’s next for gene editing? After ‘knock-out’, time for ‘knock-in’

Katie Odgaard, Zyme Communications Ltd.Tel: +44 (0) 7787 502 947 Email: [email protected] Amber Bielecka, Consilium Strategic Communications.Tel: +44 (0) 203 709 5700 Email: [email protected] 20/08/2014Article: What's next for gene editing? After 'knock-out', ... [Published Noodls - Aug 20 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Horizon Discovery and Otsuka sign collaboration agreement

Horizon Discovery announced its Horizon CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization Inc. (OPDC) to perform in-vitro cell line screening of certain OPDC development candidates. Horizon CombinatoRx ... [Published Drug Discovery News - Aug 13 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Horizon Discovery : Article: Oncology combination drug discovery in the genomics era

12/08/2014Oncology combination drug discovery in the genomics eraMany tumour types find new ways to evade single targeted cancer drugs - hence the push to find new drug combinations to shut down all the escape routes for cancer .The last 10 years have ... [Published 4 Traders - Aug 12 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Horizon Discovery Group PLC’s “Speculative Buy” Rating Reaffirmed at Beaufort Securities (HZD)

Horizon Discovery Group PLC (LON:HZD) Horizon Discovery Group PLC (LON:HZD) opened at 170.80 on Wednesday. Horizon Discovery Group PLC has a 1-year low of GBX 144.991 and a 1-year high of GBX 218.10. The stock has a 50-day moving average of GBX 169.7 ... [Published American Banking News - Forex - Aug 06 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Emmanuelle Charpentier to advise Horizon Discovery

Company: Horizon Discovery Group PlcAppointee: Emmanuelle CharpentierLocationUnited KingdomEmmanuelle Charpentier of the Hannover Medical School in Germany is one of three experts in gene editing to join the scientific advisory board of Horizon Discovery ... [Published MedNous - Aug 05 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Otsuka, Horizon CombinatoRx Sign $835K In Vitro Cell Line Screening Deal

By Lori ClapperOtsuka Pharmaceutical Development and Commercialization (OPDC) has inked a $846 thousand deal with Horizon CombinatoRx , a division of the UK-based business Horizon Discovery, to perform in vitro cell line screening of certain OPDC drug ... [Published Bioresearch Online - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Horizon Discovery and Otsuka sign collaboration agreement

Horizon Discovery Group has announced its Horizon CombinatoRx division has been contracted by Otsuka Pharmaceutical Development and Commercialization (OPDC) to perform in vitro cell line screening of certain OPDC development candidate(s).Pursuant to the ... [Published European Pharmaceutical Manufacturer - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 4 reports

Otsuka, Horizon team up on early-stage development

Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments. Under the agreement, Horizon well lend out its tools for screening ... [Published Fierce CRO - Jul 28 2014]

Quotes

...This new quarry site is adjacent to the company's existing operations in Prilep. Mr Gilbert commented: "Following the placing to raise £4.75m last month, we are pleased to already be on track with regards to the acquisition. Sivec is a highly sought after marble and key for the development of Fox Marble's portfolio." The Stock Market Show, which is hosted by the London Stock Exchange (LSE), takes place at The Business Design Centre in Islington, London, on Saturday...
"With combination screens, the aim is to identify a second drug that increases the potency of the first drug or increases overall efficacy"
Edwin Rock, M D , Ph D , Senior Director, Global Clinical Development, OPDC, said:  "As combination therapies emerge as the standard of care in a range of indications, it is important that we identify effective multi-target mechanisms. Using the Horizon CombinatoRx platform to explore our clinical stage programs in the context of combinations may provide us with information to guide development."
"This has been a strong start to the financial year and we are encouraged by Horizon's progress versus the objectives set at our recent IPO. As stated following the acquisition of CombinatoRx on June 2nd our financial year revenues will be weighted towards the second half of the year. Based on trading during the first six months we are confident of delivering a strong performance for the year. "We have also further strengthened our Board with the appointment of Dr Susan Galbraith and Mrs. Susan Searle, two highly experienced business leaders with directly relevant experience of our key customer demographics and the public markets. In line with our strategy we have also continued to build our sales, marketing and distribution footprint in European, North-American and Asia-Pacific markets. We are encouraged by current trading and excited by the year ahead." For further information from Horizon Discovery Group plc, please contact:"

More Content

All (99) | News (60) | Reports (0) | Blogs (38) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Getech to brief investors at first ever Stock [Published Telegraph - 13 hours ago]
Chaarat Gold's CEO to speak at Stock Market Show [Published Stock Market Wire - Aug 26 2014]
Premier African Minerals to brief investors at ... [Published Stock Market Wire - Aug 26 2014]
Life science investor interest highest for 10 y... [Published Business Weekly UK - Aug 21 2014]
GEN Touch: A New App For Our Readers [Published Genetic Engineering News - Aug 21 2014]
Growth on the agenda [Published Shares Magazine - Aug 21 2014]
Article: What’s next for gene editing? After ‘k... [Published Noodls - Aug 20 2014]
Fox Marble to brief investors at Stock Market S... [Published Stock Market Wire - Aug 20 2014]
KISS team cycles from London to Cambridge, rais... [Published Cambridge Network - Aug 14 2014]
Horizon Discovery and Otsuka sign collaboration... [Published Drug Discovery News - Aug 13 2014]
Horizon Discovery : Article: Oncology combinati... [Published 4 Traders - Aug 12 2014]
Cambridge Index rises 1.8% [Published NW Brown Group Limited - Aug 11 2014]
Oncology combination drug discovery in the geno... [Published pharmaphorum - Aug 11 2014]
Research Analysts’ Ratings Reiterations for Aug... [Published American Banking News - Forex - Aug 06 2014]
Horizon Discovery Group PLC’s “Speculative Buy”... [Published American Banking News - Forex - Aug 06 2014]
Beaufort Securities Breakfast Today including R... [Published Proactiveinvestors United Kingdom RSS feed - Aug 06 2014]
Emmanuelle Charpentier to advise Horizon Discovery [Published MedNous - Aug 05 2014]
Horizon Discovery Adds Three Eminent CRISPR Exp... [Published Technology Networks - Aug 05 2014]
July deals another blockbuster for Cambridge [Published Business Weekly UK - Aug 04 2014]
Meet GEN's Publisher Mary Ann Liebert [Published Genetic Engineering News - Aug 02 2014]
United States : OPDC ratifies $846 thousand con... [Published HispanicBusiness.com - Aug 01 2014]
Otsuka, Horizon CombinatoRx Sign $835K In Vitro... [Published Bioresearch Online - Jul 31 2014]
AstraZeneca signs $2bn deal to buy Almirall res... [Published PMLive - Jul 31 2014]
AIM : AIM Notice - 31/07/2014 [Published Investegate - Jul 31 2014]
Horizon Discovery and Otsuka sign collaboration... [Published European Pharmaceutical Manufacturer - Jul 30 2014]
Otsuka, Horizon team up on early-stage development [Published Fierce CRO - Jul 28 2014]
Additional Listing [Published TrustNet - Jul 28 2014]
Horizon Discovery and Otsuka Pharmaceutical Dev... [Published Fierce CRO - Jul 28 2014]
Beaufort Securities Breakfast Alert including C... [Published Proactive Investors.co.uk - Jul 28 2014]
Horizon, Otsuka ink contract agreement to carry... [Published PharmaBiz - Jul 28 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Beaufort Securities Breakfast Today Including C... [Published Proactiveinvestors United Kingdom website - Jun 13 2014]
Market opening: Markets are likely to open lower today. FTSE 100 futures were trading 23.5 points down at 7:00 am. New York: Wall Street closed in the red as escalating tensions in Iraq triggered concerns about oil supply. Shares of airline and food ...
Horizon completes acquisition of CombinatoRx Se... [Published PBR - News - Jun 03 2014]
UK-based Horizon Discovery Group has completed the acquisition of the CombinatoRx service business (known as the combination high throughput screening (cHTS) business) and related assets from US-based biopharmaceutical firm Zalicus for £4.74m ($8m). ...
Zalicus Announces Closing of cHTS Service Busin... [Published Business Wire Health News - Jun 02 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus closed the sale of its combination High Throughput Screening (cHTS) platform and related assets to Horizon Discovery Group for $8 million ...
Horizon Discovery to acquire CombinatoRx servic... [Published PBR - News - May 19 2014]
Horizon Discovery has agreed to acquire the CombinatoRx service business (known as the combination high throughput screening (cHTS) business) and related assets from Zalicus, a biopharmaceutical company that discovers and develops novel treatments for ...
Horizon to acquire CombinatoRx and assets from ... [Published BvDEP Zephyr Editorial News - May 15 2014]
UK-based Horizon Discovery Group has agreed to acquire the ConbinatoRx service business and related assets from Zalicus, a global pharmaceutical company, for GBP 4.74 million in cash.... ...
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.